Qian Yuchen, Li Pan, Lv Bin, Jiang Xiaoqing, Wang Ting, Zhang Han, Wang Xiaoying, Gao Xiumei
State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Sci Rep. 2017 Nov 13;7(1):15431. doi: 10.1038/s41598-017-15819-2.
Ginseng, a popular herbal remedy, is often used in combination with other drugs to achieve the maximum therapeutic response. Shenfu (SFI) and Shenmai injection (SMI) have been widely used to treat cardiovascular disease in China. Our study explored the cardiovascular protection of SFI and SMI in eNOS knockout mice to investigate the differences and similarities of the two ginseng-combinations. Transthoracic echocardiography was performed to evaluate the left ventricular structure and function at baseline and 3, 7, and 14 days after drug administration. Agilent Gene Expression microarrays were used to demonstrate the gene expression profiling of the thoracic aorta. Ingenuity Pathway Analysis was performed to evaluate the mechanism improved by SFI and SMI in eNOS knockout mice. Both SFI and SMI could modulate Gadd45 Signaling from TOP15 canonical pathways. Moreover, SFI showed a better effect in the early treatment stage and improved myocardial function via GATA4, GATA6 and COL3A1. Meanwhile, SMI exerted better protective effects at the chronic stage, which may be related to endothelium protection by VEGFA and ACE. The advantage of multi-target by drug combination in progression of complex diseases should be noticed. The appropriate adjustment of drug combination could lead to a better accurate medical care in clinic.
人参是一种常用的草药疗法,常与其他药物联合使用以达到最大治疗效果。参附(SFI)和参麦注射液(SMI)在中国已被广泛用于治疗心血管疾病。我们的研究探讨了SFI和SMI对eNOS基因敲除小鼠的心血管保护作用,以研究这两种人参复方的异同。在给药前及给药后3天、7天和14天进行经胸超声心动图检查,以评估左心室结构和功能。使用安捷伦基因表达微阵列来展示胸主动脉的基因表达谱。进行 Ingenuity 通路分析以评估SFI和SMI在eNOS基因敲除小鼠中改善的机制。SFI和SMI均可调节TOP15经典通路中的Gadd45信号。此外,SFI在早期治疗阶段显示出更好的效果,并通过GATA4、GATA6和COL3A1改善心肌功能。同时,SMI在慢性期发挥更好的保护作用,这可能与VEGFA和ACE对内皮的保护有关。应注意药物联合在复杂疾病进展中的多靶点优势。药物联合的适当调整可在临床上带来更精准的医疗。